Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli (Naples), Italy.
Allergy. 2010 Jun 1;65(6):698-711. doi: 10.1111/j.1398-9995.2009.02254.x. Epub 2009 Nov 11.
Palmitoylethanolamide (PEA) is an anti-inflammatory mediator that enhances the activation by anandamide (AEA) of cannabinoid receptors and transient receptor potential vanilloid type-1 (TRPV1) channels, and directly activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha). In mice, 2,4-dinitrofluorobenzene (DNFB)-induced contact allergic dermatitis (CAD) in inflamed ears is partly mediated by the chemokine Monocyte Chemotactic Protein-2 (MCP-2) and accompanied by elevation of AEA levels. No datum is available on PEA regulation and role in CAD.
We examined whether PEA is produced during DNFB-induced CAD, and if it has any direct protective action in keratinocytes in vitro.
Eight- to ten-week-old female C57BL/6J wild-type and CB(1)/CB(2) double knock-out mice were used to measure PEA levels and the expression of TRPV1, PPAR-alpha receptors and enzymes responsible for PEA biosynthesis and degradation. Human keratinocytes (HaCaT) cells were stimulated with polyinosinic polycytidylic acid [poly-(I:C)], and the expression and release of MCP-2 were measured in the presence of PEA and antagonists of its proposed receptors.
2,4-Dinitrofluorobenzene increased ear skin PEA levels and up-regulated TRPV1, PPAR-alpha and a PEA-biosynthesizing enzyme in ear keratinocytes. In HaCaT cells, stimulation with poly-(I:C) elevated the levels of both PEA and AEA, and exogenous PEA (10 microM) inhibited poly-(I:C)-induced expression and release of MCP-2 in a way reversed by antagonism at TRPV1, but not PPAR-alpha. PEA (5-10 mg/kg, intraperitoneal) also inhibited DNFB-induced ear inflammation in mice in vivo, in a way attenuated by TRPV1 antagonism.
We suggest that PEA is an endogenous protective agent against DNFB-induced keratinocyte inflammation and could be considered for therapeutic use against CAD.
棕榈酰乙醇酰胺(PEA)是一种抗炎介质,可增强大麻素受体和瞬时受体电位香草酸型 1(TRPV1)通道对花生四烯酸(AEA)的激活,并直接激活过氧化物酶体增殖物激活受体-α(PPAR-α)。在小鼠中,2,4-二硝基氟苯(DNFB)诱导的炎症耳接触过敏性皮炎(CAD)部分由趋化因子单核细胞趋化蛋白-2(MCP-2)介导,并伴有 AEA 水平升高。目前尚无关于 PEA 调节和 CAD 作用的数据。
我们检查了 PEA 是否在 DNFB 诱导的 CAD 中产生,以及它在体外角质细胞中是否具有直接的保护作用。
使用 8-10 周龄的雌性 C57BL/6J 野生型和 CB(1)/CB(2)双敲除小鼠测量 PEA 水平以及 TRPV1、PPAR-α 受体和负责 PEA 生物合成和降解的酶的表达。用聚肌苷酸聚胞苷酸[poly-(I:C)]刺激人角质形成细胞(HaCaT)细胞,并在 PEA 及其拟议受体拮抗剂存在的情况下测量 MCP-2 的表达和释放。
2,4-二硝基氟苯增加了耳部皮肤 PEA 水平,并上调了耳部角质形成细胞中的 TRPV1、PPAR-α 和一种 PEA 生物合成酶。在 HaCaT 细胞中,poly-(I:C)刺激可使 PEA 和 AEA 水平升高,外源性 PEA(10μM)以 TRPV1 拮抗逆转的方式抑制 poly-(I:C)诱导的 MCP-2 表达和释放,但不抑制 PPAR-α。PEA(5-10mg/kg,腹腔内)也可抑制体内 DNFB 诱导的小鼠耳部炎症,其方式可通过 TRPV1 拮抗作用减弱。
我们认为 PEA 是一种内源性保护剂,可防止 DNFB 诱导的角质形成细胞炎症,可考虑用于治疗 CAD。